Current Trends in Pharmacy and Pharmaceutical Chemistry

Online ISSN: 2582-5062

Current Trends in Pharmacy and Pharmaceutical Chemistry is the official Journal of Ateos Foundation of Science Education and Research, hosted and Managed IP Innovative Publications Pvt. Ltd, New Delhi, India. Current Trends in Pharmacy and Pharmaceutical Chemistry is an open access, peer-reviewed quarterly international journal publishing since 2019 and is published under auspices of the Ateos Foundation of Science Education and Research. It aims to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 714

PDF Downloaded: 261


Get Permission Bhamre Vaibhav G., Deore Pranjal D., Amrutkar Rakesh D, and Patil Vinod R.: Polyphenols: The interactions with CYP 450 isoenzymes and effect on pharmacokinetics of drugs

Journal Information

Journal ID (nlm-ta): Innovative Publication

Journal ID (publisher-id): Innovative Publication

Journal ID (journal_submission_guidelines): https://www.ctppc.org/

Title: Current Trends in Pharmacy and Pharmaceutical Chemistry

ISSN: 2582-5062

Article Information

Copyright: 2022

Date received: 5 December 2021

Date accepted: 20 January 2022

Publication date: 17 February 2022

Volume: 4

Issue: 1

DOI: 10.18231/j.ctppc.2022.004

Polyphenols: The interactions with CYP 450 isoenzymes and effect on pharmacokinetics of drugs

[] Bhamre Vaibhav G.[1]

Email: vaibhav.bhamre@gmail.com

Designation:

Associate Professor

[] Deore Pranjal D.[2]

Designation:

Jr. Data Analyst

[] Amrutkar Rakesh D[3]

Designation:

Associate Professor

[] Patil Vinod R.[4]

Designation:

Assistant Professor

 

Dept. of Pharmaceutics, K. K. Wagh College of Pharmacy Nashik, Maharashtra India

Cognizant Technology Solution Pune, Maharashtra India

Dept. of Pharmaceutical Chemistry, K. K. Wagh College of Pharmacy Nashik, Maharashtra India

Dept. of Pharmacology, S.P. H college of Pharmacy Malegaon, Maharashtra India

Abstract

Recent clinical studies demonstrated that certain natural polyphenols like flavonoids present in dietary supplements modify the pharmacokinetics of some co-administered drugs. Number of herbal remedies interact selectively with different CYP450 isoenzymes and hence alter CYP- mediated drug metabolism and pharmacokinetics. Drug-polyphenol interaction may alter drug bio availability through altered absorption, distribution and metabolism. There is need to collect clinical evidences to support whether the effect of drugs and polyphenols co-administration rather than relying on in-vitro experiments or animal studies. Herbal drugs containing variety of polyphenols interact with CYP450 enzymes leading to either induction or inhibition of CYPs which alters the pharmacokinetic parameters of their respective substrate drugs. This information will be helpful for physicians and pharmacists to alleviate risks associated with polyphenolic remedies as well as to realize the benefits of alternative medicine.

Introduction

More than 8000 polyphenolic compounds have been identified in various plant species, having several important functions. The phenolic groups in polyphenols can accept an electron to form relatively stable phenoxyl radicals, thereby disrupting chain oxidation reactions in cellular components.1 In addition to fruits and vegetables, leaves, nuts, seeds, barks and flowers are also rich sources of polyphenols.2 On the basis of in vivo or in vitro evidence, inhibition of the CYP forms responsible for the metabolism of co-administered drugs has been proposed as the mechanism responsible for the pharmacokinetic interactions caused by flavonoids.3 Flavonoids have high potencies and selectivities for inhibition of CYPlA isoenzymes.4 Polyphenols may be classified into different groups as a function of the number of phenol rings that they contain and of the structural elements that bind these rings to one another. The main classes include phenolic acids, diferuloylmethanes, flavonoids, stilbenes and lignans. Phenolic acids are further classified as hydroxycinnamic acids (e.g. Caffeic acid, Caftaric acids) and hydroxybenzoic acids (e.g. Ellagic acid, Gallic acid, Corilagin). Diferuloylmethanes are phenolic compounds with two aromatic rings substitued with hydroxyls, and linked by aliphatic chain containing carbonyl groups (e.g. Curcumin).

Table 1

Sources of polyphenols with their interaction with different CYP subfamilies

Fruits/ Herbs

Polyphenols

Interaction with CYP450 isoforms

Apple juice

Quercetin, Phloretin, Rutin, Phlorizin, Phloretin, (-)-Epicatechin, (+)-Catechin, Chlorogenic acid5

Quercetin and phloretin inhibit CYP1A6

Beet juice

Betacyanin7

---

Black pepper

Piperine, Alkamides, Wisanine, Dipiperamide D, Dipiperamide E, Piptigrine8

CYP3A415, Piperine, dipiperamides D and E inhibit CYP2D6 9, 10

Blackberries

Ellagic acid, Tannins, Ellagitannins, Quercetin, Gallic acid, Anthocyanins, Cyanidins11, 12

---

Blackcurrant

Delphinidin-3-O-Glucoside, Delphinidin-3-O-Rutinoside, Cyanidin-3-O-Glucoside, Cyanidin-3-O-Rutinoside13

Inhibits CYP1A1 14

Broccoli

Β-Carotene, Lutein15

Induces CYP1A2 and CYP2A616

Cocoa

Catechin, Epicatechin, Caffeine, Theobromine, Theophylline17

Crude cocao inhibits CYP1A18

Cranberries

Cyanidin, Peonidin, Quercetin19, 20

Inhibits CYP2C9 21

Turmeric

Curcumin

Inhibit CYP1A2, Induce CYP2A6 22

Green tea

Epigallocatechin-3-Gallate (EGCG), Epigallocatechin (EGC), Epicatechin-3-Gallate (ECG), Epicatechin, Caffine

Caffine induces CYP1A223

Gingko biloba extract

Terpenoids , Flavonoids, Amentoflavone

Inhibit CYP2C9, CYP1A2, CYP2E1, CYP3A424

Grape juice

Catechins, Ellagic acid, Myricetin, Quercetin, Kaempferol, Trans-Resveratrol, Syringetin, Syringetin 3-O-Galactoside, Laricitrin, Laricitrin 3-O-Galactoside, Delphinidin, Cyanidin, Petunidin, Peonidin, Malvidin25, 26, 27

Quircetin inhibits CYP 1A2, trans-resveratrol inhibits CYP1A1, CYP1A2, CYP1B1,CYP2E1 28, 29

Grapefruit

Naringin, Bergamottin, Dihydroxybergamottin

Naringin inhibits CYP3A4 30

Lettuce

Mono-Caffeoyl Tartaric acid, Chicoric acid, 5-Caffeoylquinic acid (Chlorogenic acid), 3,5-Di-O-Caffeoylquinic acid (Isochlorogenic acid), Quercetin 3-O-(6-O-Malonylglucoside)-7-O-Glucoside, Quercetin 3-O-Glucuronide, Quercetin 3-O-Glucoside, Luteolin 31, 32

---

Pineapple

Bromelain33

Inhibits CYP2C9 34

Onion

Spiraeoside (Quercetin-4´-O-Β-D-Glucoside), Rutin, Quercetin5

Induces CYP 1A, CYP 2B, Inhibits CYP 2E1 35, 36

Licorice root

Tannic acid, Glycyrrhizin5

Glycyrrhizin induces CYP3A, CYP1A2 37

Wanmi peach

Chlorogenic acid, Keracyanin, Quercetin-3-Rutinoside 38

---

Persimmon

Astragalin, Hyperin, Quercetin, Isoquercitin, Myricetin, Kaempferol, Scopoletin, Rutin

Myricetin inhibits CYP3A4, CYP2C9 39

Plums

Gallic acid, Tannins 40

Inhibits CYP1A1 41

Pomegranates

Catechins, Gallocatechins, Ellagitannins, Punicalagins, Prodelphinidins, Delphinidin, Cyanidin, Pelargonidin 42, 43

Inhibits CYP3A4 44

Raspberry

Quercetin, Gallic acid, Anthocyanins, Cyanidins, Pelargonidins, Catechins, Kaempferol, Ellagitannin 45

---

Soybean

Genistein, Daidzein, Phytic acid 46, 47

Induces CYP1A1, CYP2D1, Inhibits CYP3A1, CYP2D2 48

Spinach

Lutein, Zeaxanthin 49

---

St. John’s wart

Rutin, Hyperoside, Isoquercetin, Quercitrin, Quercetin, I3,II8-Biapigenin, Amentoflavone, Astilbin, Miquelianin, Chlorogenic acid, 3-O-Coumaroylquinic acid, Hypericin, Pseudohypericin, Protohypericin, Hyperforin, Protopseudohypericin, Adhyperforin 50, 51

Induces CYP3A4, CYP2C9 52

Tangerines

Nobiletin, Limonene, Myrcene 53

Induces CYP3A4 54

Tomatoes

Lutein, Lycopene 55, 56

Induces CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP3A 57

Orange

Hesperidin 58

Inhibits CYP3A4 59

Strawberries

Cyanidins, Pelargonidins, Procyanidins, Catechins, Gallocatechins, Epicatechins, Kaempferol, Quercetin, Ellagic acid, Gallic acid, Cinnamic acid, Coumaric acid, Caffeic acid, Ferulic acid, Ellagitannins, Gallotannins, Resveratrol60

---

Milk thistle

Silybin, Silymarin61

Silybin Inhibits CYP2D6, CYP 2C9, Silymarin inhibits CYP3A462

Table 2

Different herbal drugs and their effect on pharmacokinetics of some drugs

Fruit Juices/ Herbal Extracts

Interacting drug

Pharmacokinetic alterations

Apple Juice

Fexofenadine

A significant decrease in the fexofenadine AUC was observed compared with water (1342±519 vs. 284±79.2 ng·h/ml, P<0.05).63

Cranberry Juice (CJ)

Nifedipine

AUC of Nifedipine was approximately 1.6-fold higher when CJ injected intraduodenally.64

Grapefruit Juice (GFJ)

1.Talinolol

1. GFJ decreased the talinolol serum AUC and Cmax, and urinary excretion values to 56% (P < .001), 57% (P < .001), and 56% (P < .001), respectively, of those with water. No effect on renal clearance, elimination half-life, or Tmax.65

2.Nilotinib

2. Concurrent intake of GFJ increased the nilotinib Cmax by 60% and serum AUC0-∞ by 29% but did not affect Tmax or t1/2 of nilotinib.66

3.Tramadol

3. Tramadol Tmax was increased from 1.33 to 1.70 h after GFJ treatment, plasma Cmax decreased from 490 to 270 ng/ml and AUC decreased from 11,610 to 5,890 h·ng/ml with GFJ treatment.67

4.Nisoldipine

4. Cmax of nisoldipine was significantly increased after GFJ intake.68

Orange Juice (OJ)

1.Levofloxacin

1. Plasma Cmax of Levofloxacin decreased from 3.49 ± 0.75µg/ml to 2.57± 0.46µg/ml when taken with OJ. Serum AUC0-∞ value was also reduced by 17.33%; AUC0-24 was decreased by 14.98%.69

2.Fexofenadine

2. OJ decreased the oral exposure of fexofenadine by 31% in rats.70

3.Indinavir

3. Coadministration of Seville OJ and indinavir resulted in significant increase in indinavir Tmax from 1.25 to 1.87h; p < 0.05.71

4.Itraconazole

4. Cmax and AUC0-48 of itraconazole were 1.1-fold to 1.3-fold higher when co-administered with OJ, than that with water.72

5.Cyclosporine A

5.OJ significantly increased the AUC and Cmax, and decreased the Tmax of cyclosporine A.73

6.Atenolol

6. OJ decreased plasma Cmax of atenolol by 49% (range 16-59%, P<0.01), and plasma atenolol AUC0-33 by 40% (range 25-55%, P<0.01). The amount of atenolol excreted into urine was decreased by 38% (range 17-60%, P<0.01). 74

7.Celiprolol

7. OJ reduced plasma Cmax of celiprolol by 89% (P< .01) and plasma AUC by 83% (P< .01). Tmax increased from 4 to 6 h (P< .05), t1/2 was prolonged from 4.6 to 10.8 h (P = .05). Urinary excretion of celiprolol was reduced by 77% (P < .01). 75

8.Ethionamide

8.Cmax was increased by OJ (9%), Tmax delayed by (12%). 76

Pomegranate Juice (PJ)

Tolbutamide

PJ significantly increased the AUC of tolbutamide by 22%.77

St John's Wort

1.Fexofenadine

1. A single dose of St John's wort increased plasma Cmax of fexofenadine by 45% (P< .05) and decreased the oral clearance by 20% (P< .05). Compared with the single-dose treatment phase, long-term St John's wort caused 35% (P< .05) decrease in Cmax and 47% (P< .05) increase in fexofenadine oral clearance. 78

2.Warfarin

2. Apparent clearances of S-warfarin after warfarin alone or with St John's wort 198 ± 38 ml/h, and 270 ± 44 ml/h. 79

3.Imatinib Mesylate

3.Reductions of 32% (p=0.0001) in the median AUC0-∞, 29% (p=0.005) in Cmax and 21% (p=0.0001) in t1/2 of Imatinib Mesylate. 80

Ginseng

Warfarin

Apparent clearances of S-warfarin after warfarin alone or with ginseng 198 ± 38 ml/h and 220 ± 29 ml/h 79

Tangerine Juice

Midazolam

Reduced the AUC0-1.5 of midazolam by 39% and prolonged the Tmax (P < .05) without affecting the total AUC values, t1/2 values.81

Green Tea Extract (GTE)

Clozapine

Tmax was significantly increased by GTE. The mean total AUC0-∞ and Cmax in GTE group were significantly lower than those of controls. Induced a about 2-fold increase in hepatic CYP1A2 levels.82

Table 3

Brief summary of effect of different polyphenols on pharmacokinetics of some drugs

Polyphenol

Interacting drug

Pharmacokinetic alterations

Apigenin

Raloxifene

Apigenin with raloxifene in a 1:2 ratio by weight resulted in 55% and 37% increase in the Cmax and AUC of raloxifene, respectively. When the ratio of 1:1 was administered, the Cmax and AUC of intact raloxifene were increased by 173% and 97% respectively.83

Baicalin and Baicalein

1.Cyclosporine

1. Baicalin and baicalein elevated Cmax of cyclosporine by 408.1 % and 87.5 % and increased the AUC0 - 540 by 685.3 % and 150.2 %, respectively. 84

2.Doxorubicin (DOX)

2. AUC0-∞ and Cmax of DOX were significantly higher when given with baicalein.85

Caffeic Acid

L-Dopa, 3-O-Methyldopa (3-OMD)

Decreased about 22% of the peripheral formation of 3-OMD and about 31% of the Cmax of 3-OMD, caffeic acid improves the bioavailability of L-dopa in rabbit plasma.86

(+)-Catechin

Carbamazepine

(+)-Catechin caused a delayed absorption of carbamazepine, as evidenced by shift of Tmax from 2 h to 6 h.87

Hesperidin

1.Montelukast

1.Reduction in the AUC0-∞ of montelukast (P = 0.032).88

2.Diltiazem

2. AUC0-∞ was significantly (5 mg/kg, P < 0.05; 15 mg/kg, P < 0.01) increased by 48.9-65.3% and Cmax was significantly (P < 0.05) increased by 46.7-62.4% in the presence of hesperidin (5 or 15 mg/kg). The absolute bioavailability (F) of diltiazem with hesperidin was significantly (5 mg/kg, P < 0.05; 15 mg/kg, P < 0.01) higher than that in the control group. 89

3.Verapamil

3. Hesperidin significantly (p<0.01) increased plasma AUC of verapamil by 71.1-96.8% and Cmax by 98.3-105.2%. Hesperidin significantly (p<0.01) decreased its total plasma clearance (CL/F) by 41.6-49.2% in rats. 90

Curcumin

1.Talinolol

1. Reduced AUC0- ∞ of talinolol from 1860.0 ±377.9 to 1246.0 ±328.2 ng.h/mL, the Cmax were significantly decreased from 147.8 ± 63.8 to 106.4 ± 39.9 ng/mL, and the CL/F was increased from 27.9 ± 5.5 to 43.1± 13.4 L/h (p < 0.05). 91

2.Celiprolol

2. The Cmax, AUC0–8, and total AUC of celiprolol were, respectively, 1.9- (p 0.01), 1.6- (p 0.01), and 1.3-fold (p 0.02) greater for rats in the treated group. CLoral was decreased by 22% (p 0.01). 92

3.Midazolam

3. Rats in the treatment group showed higher AUC0–4 (2.6-fold, p 0.04) and total AUC (3.8-fold, p 0.03) values, as well as lower CLoral (75% lower, p 0.02) values, compared with control. 92

4.Etoposide

4. Curcumin (2 or 8 mg/kg) increased significantly the oral bioavailability, AUC and Cmax of etoposide. 93

Daidzein

Theophylline

Comparing the kinetics parameters of theophylline alone of day 1 with those of 10-day daidzein treatment, the AUC0-48, AUC0- ∞ , Cmax and t1/2 were significantly increased by 33.57 ± 21.75% (P< 0.05), 33.77 ± 21.45% (P<0.05), 23.54 ± 16.93% (P< 0.05) and 41.39 ± 45.92% (P=0.011), respectively. 94

Diosmetin

Diclofenac

Diosmetin increased markedly the Km (substrate concentration yielding 50% of Vmax) of the reaction without affecting the Vmax of reaction.3

Diosmin

Metronicazole

Metronicazole plasma AUC0-X and Cmax were significantly higher after diosmin pretreatment by (mean) 27% and 24%, respectively.95

Epigallocatechin Gallate (EGCG)

1.Verapamil

1. Compared with the controls, both the AUC and the relative bioavailability of verapamil were significantly (p 0.01) increased by 74.3- 111% in the presence of EGCG.96

2.Tamoxifen

2. Compared with the oral control group plasma AUC and the Cmax of tamoxifen significantly (P<0.05 for 3 mg/kg of EGCG, P<0.01 for 10 mg/kg of EGCG) increased 48.4-77.0 and 57.1-89.7%, respectively. The relative bioavailability of tamoxifen was 1.48-1.77-fold greater than that of the control group.97

Genistein

1.Paclitaxel

1. Genistein significantly (p<0.05) increased the AUC (54.7% greater) of orally administered paclitaxel, which was due to the significantly (p<0.05) decreased CL/F value of paclitaxel (35.2% lower). Genistein also increased the Cmax of paclitaxel significantly (p<0.05 by 3.3mg/kg, 66.8% higher; p<0.01 by 10mg/kg, 91.8% higher). The absolute bioavailability (F) of paclitaxel elevated from 0.016 to 0.020-0.025 in the presence of genistein and the relative bioavailability (Fr) of orally administered paclitaxel was increased from 1.26- to 1.55-fold.98

2.Carbamazepine

2. Bioavailability reduced, AUC0-t, Cmax, Tmax reduced, Plasma CL increased, due to induction of CYP3A4. 99

3.Omeprazole

3. Bioavailability increased, AUC0-t, Cmax, increased, Plasma CL reduced, due to inhibition of CYP2C9. 99
Table 0

Table 3 Cont....

Kaempferol

1.Etoposide

1. The presence of kaempferol significantly (4 mg/kg, P < 0.05; 12 mg/kg, P < 0.01) increased the plasma AUC and Cmax of the oral etoposide. Kaempferol decreased significantly (4 or 12 mg/kg, P < 0.05) the CL/F value of oral etoposide.100

2.Nifedipine

2. Plasma Cmax of the three treated groups were 0.51, 0.70 and 0.81 μg/ml, respectively. The AUC0-8 values were 1.81, 2.83 and 3.63 μg/h/ml, respectively. The Cmax, AUC0-8 and the mean retention time MRT0-8 of Nifedipine were significantly increased by oral treatment with kaempferol(P 0.01). 101

3.Tamoxifen

3. In the presence of kaempferol, plasma AUC0-∞ of tamoxifen was significantly greater; Cmax and F were greater than those without kaempferol. 102

Luteolin

γ-Hydroxybutyrate (GHB)

Compared with the GHB alone, the AUC of GHB was significantly decreased from 170±40 mg/ml.min in the control rats to 113±21 mg/ml.min (p<0.05) for luteolin 10 mg/kg group. In contrast, the total clearance of GHB was significantly increased from 6.19±1.59 ml/min/kg to 9.05±1.43 ml/min/kg(p<0.05) in the luteolin 10 mg/kg group.103

Morin

1.Diltiazem

1. Compared with the control group, pretreatment of morin significantly increased the absorption rate constant (Ka) and Cmax of diltiazem (p<0.05, p<0.01). Plasma AUC in morin treated rats were significantly higher than that in the control group (p<0.05, p<0.01). Relative bioavailability (RB%) in rats pretreated with morin was increased by 1.36- to 2.03-fold. 104

2.Etoposide

2. Orally morin (15 mg/kg) significantly increased the AUC (45.8%), Cmax (32.0%) and the absolute bioavailability (35.9%) of oral etoposide compared with the control. 105

3.Nicardipine

3. Morin significantly increased (P< 0.01, 67.8–112%) the plasma AUC and Cmax (P< 0.01, 53.5–93.1%) of oral nicardipine. Morin (7.5 and 15 mg/kg) significantly decreased (P< 0.01, 40.4–52.8%) the CL/F of nicardipine compared with the control group. 106

4.Paclitaxel

4. Compared to the control, pretreatment with morin increased Cmax and AUC of paclitaxel by 70–90% and 30–70%, respectively. 107

5.Tamoxifen

5. Morin significantly (p<0.05) increased the Ka of tamoxifen compared to the control group, and the plasma AUC and Cmax were significantly (p<0.05) higher, especially by 1.5 and 7.5 mg/kg of morin coadministration (p<0.01). The absolute bioavailability (AB %) were from 26.4% to 45.4% in the presence of morin, much higher than the control, 16.3%. The relative bioavailability (RB%) was 1.62-to 2.79-times higher than the control group. 108

Myricetin

1.Doxorubicin (DOX) 2.Losartan

1. Compared to the control group, myricetin significantly (p < 0.05, 2 mg/kg; p < 0.01, 10 mg/kg) increased the plasma AUC (51-117% greater) of oral DOX. Myricetin also significantly (p < 0.05, 2 mg/kg; p < 0.01, 10 mg/kg) increased Cmax of DOX. The relative bioavailability of oral DOX was increased by 1.51- to 2.17-fold. 109 2. Myricetin (2 or 8 mg/kg) increased the plasma AUC of losartan by 31.4-61.1% and Cmax by 31.8-50.2%. 110

3.Tamoxifen

3. Compared with the oral control group, the plasma AUC0–∞ and the Cmax of tamoxifen were significantly (P < 0.05, 2 mg/kg; P < 0.01, 8 mg/kg) increased by 41.8–74.4 and 48.4–81.7%, respectively. The relative bioavailability (RB) was 1.14- to 1.74-fold greater than that of the control group. 111

Naringin

1.Paclitaxel

1. Compared to the control, naringin increased the Cmax of paclitaxel significantly (p<0.01). The plasma AUC and Cmax of paclitaxel with naringin significantly higher (p<0.01) than the control. The half-life t1/2 was significantly (p<0.05) longer than the control. The absolute bioavailability (AB, of paclitaxel with naringin was significantly higher (3.5-6.8%, p<0.01) than the control (2.2%). 112

2.Tamoxifen

2. Naringin pretreated animals showed significantly (p<0.01) increased plasma AUC and Cmax. The absolute bioavailabilities (AB%) of tamoxifen in naringin pretreated animals were enhanced versus control (from 32.8% to 47.1%), and the relative bioavailabilities (RB%) of tamoxifen in the naringin pretreated groups were 2.02-2.88 times higher than that in the control. 113
Table 0

Table 3 Cont....

Piperine

1.Carbamazepine

1. Piperine increased AUC0-12 (p<0.001), average Css (p<0.001), t1/2el (p<0.05) and a decreased Kel (p<0.05). Cmax (p<0.01) and Tmax (p<0.01) were increased significantly. 114

2. Fexofenadine

2. Piperine increased AUC of fexofenadine by 180% to 190% in rats. The bioavailability of fexofenadine was increased by approximately 2-folds via the concomitant use of piperine.115

3. Phenytoin

3. Significant increase in AUC0-12 (p < 0.01), Cmax (p < 0.001) and Ka (p < 0.05). Piperine enhanced the bioavailability of phenytoin significantly by increasing the absorption.116

4. Propranolol

4. Earlier Tmax and a higher Cmax and AUC were observed when co-administered with piperine.117

Quercetin

1.Cyclosporine (CSP)

1.Quercetin significantly decreased the Cmax of CSP by 67.8% and reduced the AUC0−540 by 43.3%. 118

2.Fexofenadine

2. The plasma AUC of fexofenadine was increased by 55% by quercetin (2,005.3 versus 3,098.6 ng.h/ml, P<0.001) and Cmax during the quercetin phase was elevated by 68% compared to that of the placebo phase (295.3 versus 480.3 ng/ml, P=0.006). The CLoral of fexofenadine was decreased significantly by 37% after quercetin treatment (61.4 versus 38.7 L/h, P<0.001).119

3.Tamoxifen

3. Coadministration of quercetin (2.5 and 7.5 mg/kg) significantly (p < 0.05) increased the Ka, Cmax and plasma AUC of tamoxifen. The absolute bioavailability (AB%) of tamoxifen with 2.5 and 7.5 mg/kg quercetin ranged from 18.0% to 24.1%, which was significantly higher than the control group, 15.0% (p < 0.05). The relative bioavailability (RB%) of tamoxifen coadministered with quercetin was 1.20-1.61 times higher than the control group.120

Resveratrol

1.Diltiazem

1. Resveratrol (2.5 and 10 mg/kg) significantly (P< 0.05) increased the AUC of diltiazem by 47.7–59.9%, and Cmax of diltiazem by 46.1–57.0% in rats. Resveratrol (2.5 and 10 mg/kg) increased the RB of diltiazem by 1.48- to 1.60-fold.121

2.Nicardipine

2. Resveratrol significantly increased both plasma AUC (P < 0.01, 111-126%) and Cmax (P < 0.01, 105-121%), and significantly decreased CL/F (P < 0.01, 52.8-55.8%) of oral nicardipine. 122

Rutin

1.Warfarin

1. Treatment with rutin significantly decreased the elimination t1/2 of S-warfarin by 37%.123

2.Cyclosporine (CSP)

2. Rutin significantly decreased the Cmax of CSP by 63.2% and reduced the AUC0−540 by 57.2%.118

Silibinin

1.Paclitaxel

1. Silibinin significantly (p < 0.05 by 2.5 mg/kg, p < 0.01 by 10 mg/kg) increased the plasma AUC (65.8-101.7% higher) of oral paclitaxel. Silibinin significantly increased (p < 0.05 by 2.5 mg/kg, 31.0% higher; p < 0.01 by 10 mg/kg, 52.9% higher) the Cmax of paclitaxel. The relative bioavailability of oral paclitaxel was increased 1.15 to 2.02 fold.124

2.Pyrazinamide

2.Long-Term silibinin decreases AUC of Pyrazinamide from 19,300 ± 3800 to 18,200 ± 4500 (min/μg/ml), CL from 2.52 ± 0.8 to 2.30 ± 0.29 (ml/kg/min), t1/2 from 204 ± 33 to 189 ± 14 (min), and Cmax increases from 119 ± 31 to 145 ± 46 (μg/ml). 125

3.Loratadine

3. The plasma AUC and Cmax of loratadine were increased significantly (P < 0.05 for 1.5 mg/kg, P < 0.01 for 6 mg/kg) by 50.0-76.7% and 65.4-90.1%, respectively, by silybinin. The relative bioavailability of loratadine was 1.50 to 1.77 fold greater than that in the control group. 126

4.Tamoxifen

4. The plasma AUC0–∞ and Cmax of tamoxifen were significantly (p<0.05 for 2.5 mg/kg, p<0.01 for 10 mg/kg) increased by 40.2-71.3% and 45.2-78.6%, respectively, with silybinin. The relative bioavailability (RB) was 1.40 to 1.72 fold greater than that in the control group.127

5.Nifedipine

5. Nifedipine AUC was 1.13-fold higher in the silymarin period, Cmax values were 0.70-fold of those of the reference period.128

6.Talinolol

6. The Cmax of talinolol was significantly higher after silymarin administration compared to the placebo. Plasma AUC0-36 and AUC0-∞ of talinolol was increased by 36.2±33.2 and 36.5±37.9%, respectively, by silymarin. The CL/F of talinolol was decreased by 23.1±16.6% during the silymarin-treated phase.129

The major and most abundant class within the dietary polyphenols is flavonoids and is further classified as: Anthocyanidins (e.g. Cyanidin, Delphinidin, Pelargonidin) and different Anthoxanthins including Flavonols (e.g. Myricetin, Quercetin, Kaempferol), Flavanones (e.g. Naringenin, Hesperetin), Flavones (eg. Apigenin, Luteolin), Flavanols (e.g. (+)-Catechin, (-)-Epicatechin, (-)-Epicatechin 3-gallate, Morin, (-)-Epigallocatechin, (+)-Gallocatechin, Procyanidins), Isoflavones (eg. Daidzein, Genistein), and Flavonoid glycosides (eg. Rutin, Hesperidin, Naringin). Stibenes are polyphenolics exist in the form of monomers or oligomers (eg. Trihydroxy-stilbenes like Resveratrol, Trans-resveratrol). Tannins are a group of water-soluble polyphenols which are subdivided into condensed and hydrolisable tannins (eg. Catechin polymers, Epicatechin polymers, Ellagitannins, Proanthocyanidins, Sanguin, Tannic acids).130, 131, 132

Polyphenols causes induction or inhibition of CYP450 enzymes by different mechanisms. Their mechanism of inhibition of CYP includes reversible inhibition, quasi-irreversible and irreversible inhibition. Reversible inhibition can be further divided, based on enzyme kinetics, into competitive, noncompetitive, and uncompetitive. In quasi-irreversible inhibition, inhibitor is metabolically activated by the CYP enzyme, and then this inhibitory metabolite forms a stable metabolic intermediate (MI) complex with the prosthetic heme of CYP, rendering the enzyme functionally inactive. Irreversible inhibition is also called mechanism-based or suicide inhibition.133 CYP inductionis mediated by specific nuclear receptors eg. CYP3A4 induction by pregnane X receptor (PXR), constitutive androstane receptor (CAR), and glucocorticoid receptor.134 Induction of CYP1A enzymes mediated by formation of a dimer of the cytosolic aryl hydrocarbon receptor (AhR) and the AhR nuclear translocator protein (Arnt). There are also other mechanisms of CYP enzyme induction, for example ethanol induces CYP2E1 primarily by stabilizing the enzyme.135 Interaction of herbal remedies with some drugs have been assessed in clinical trials showing changes in pharmacokinetic parameters like AUC, Cmax, Tmax, CLoral, etc, possibly indicating that its polyphenols inhibit or induce CYP450 enzymes.

The aim of this paper was to review the current literature on variety of polyphenols present in fruits and herbs, their interaction with different CYP isoenzymes, and their effect on pharmacokinetics of different drug molecules.

Polyphenols present in fruits and herbs and their interaction with different cyp450 isoforms

It is now fairly established that naturally occurring dietary supplements can modulate hepatic and enterocytic CYP activity (Table 1). There is need to study the drug-polyphenol interactions to monitor and predict the possible positive or negative outcomes of their co-administration.

Effect of fruit juices and herbal extracts on pharmacokinetics of drugs

Use of herbal drugs has been increased enormously because of their efficacy coupled with decreased risk of side effects. Ever-increasing use of herbs with western medicines raises the potential for drug–herbal interactions, which may alter drug bioavailability (Table 2) through altered absorption, distribution and metabolism.40 Concomitant drug and food intake creates the opportunity for interactions that may change the oral bioavailability and resulting effectiveness or toxicity of a drug.136

Effect of specific polyphenols on pharmacokinetics of drugs

It may be of interest to determine the identity of polyphenols in fruit juices that exhibits significant effect on disposition of prescription drugs (Table 3). Understanding the nature of these chemicals would enable health care professionals to avoid food-drug interactions.137

Conclusion

Literature reveals that herbal drugs containing variety of polyphenols interact with CYP450 enzymes leading to either induction or inhibition of CYPs. Majority of the drugs in market are metabolized by the CYP450 isoenzymes present in liver and intestine. Induction or inhibition of these different CYP isoenzymes and other phase I, phase II enzymes alters the pharmacokinetic parameters of their respective substrate drugs. These pharmacokinetic alterations may lead to either beneficial or adverse effect on drug- action. In-vitro studies have demonstrated that several different types of fruit juices have the capacity to influence drug disposition, but many of these interactions are not clinically significant. This difference may be because of: a) the concentration of the inhibitors might not be high enough in the juice or b) there might be species difference in drug-metabolizing enzymes, in the case where the juices were shown to interact with drugs in animals.138

Source of Funding

None.

Conflict of Interest

None.

References

1 

M N Clifford Chlorogenic acids and other cinnamates-nature, occurrence and dietary burdenJ Sci Food Agriculture19997933627210.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D

2 

P Fresco F Borges M P M Marques C Diniz The Anticancer Properties of Dietary Polyphenols and its Relation with ApoptosisCurr Pharm Design20101611143410.2174/138161210789941856

3 

L Quintieri S Bortolozzo P Palatini Flavonoids Diosmetin and Hesperetin are Potent Inhibitors of Cytochrome P450 2C9-mediated Drug Metabolism in vitroDrug Metab Pharmacokinet20102554667610.2133/dmpk.dmpk-10-rg-044

4 

R Narayana K Reddy M S Chaluvadi M R Krishna Bioflavonoids Classification, Pharmacological, Biochemical Effects and Therapeutic PotentialIndian J Pharmacol2001331216

5 

R J Yin X F Xiao Y Y Xu X H Liu C Y Li C X Liu Research information and review on the leaves of Diospyros kaki L II. Pharmacokinetics of major active compounds of Diospyros kaki LAsian J Pharmacodynamic Pharmacokinetics201010427185

6 

P G Kapasakalidis R A Rastall M H Gordon Extraction of polyphenols from processed black currant (Ribes nigrum L.) residuesJ Agricultural Food Chem2006541140163710.1021/jf052999l

7 

L Kansanen H Mykkanen R Torronen Flavonoids and extracts of strawberry and black currant are inhibitors of the carcinogen-activating enzyme CYP1A1 in vitro19963868https://www.researchgate.net/scientific-contributions/Liisa-Kansanen-2106864932

8 

A G Świgło E Ciska K P Lemańska J Chmielewski T Borkowski B Tyrakowska Changes in the content of health-promoting compounds and antioxidant activity of broccoli after domestic processingFood Additives Contaminants20062311108898

9 

N Hakooz I Hamdan Effects of Dietary Broccoli on Human in Vivo Caffeine Metabolism: A Pilot Study on a Group of Jordanian VolunteersCurr Drug Metab20078191510.2174/138920007779315080

10 

M Abbe I Amin Polyphenols in Cocoa and Cocoa Products: Is There a Link between Antioxidant Properties and Health?Molecules20081392190221910.3390/molecules13092190

11 

M Ohno K Q Sakamoto M Ishizuka S Fujita Crude Cacao Theobroma cacao Extract Reduces Mutagenicity Induced by Benzo[a]pyrene Through Inhibition of CYP1A Activity In VitroPhytotherapy Res20092381134910.1002/ptr.2762

12 

S J Duthie A M Jenkinson A Crozier The effects of cranberry juice consumption on antioxidant status and biomarkers relating to heart disease and cancer in healthy human volunteersEur J Nutr20064521133510.1007/s00394-005-0572-9

13 

W Zheng S Y Wang Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberriesJ Agricultural Food Chem20035125021110.1021/jf020728u

14 

D Q Pham A Q Pham Interaction potential between cranberry juice and warfarinAm J Health Syst Pharm2007645490410.2146/ajhp060370

15 

Y Chen W Liu B Chen L Fan Y Han G Wang Plant Polyphenol Curcumin Significantly Affects CYP1A2 and CYP2A6 Activity in Healthy, Male Chinese VolunteersAnn Pharmacother2010446103845

16 

C S Yang J D Lambert S Sang Antioxidative and anti-carcinogenic activities of tea polyphenolsArch Toxicol20098311110.1007/s00204-008-0372-0

17 

C Gaudineau R Beckerman S Welbourn K Auclair Inhibition of human P450 enzyme by multiple constituents of the Gingko biloba extractBiochem Biophysical Res Commun2004318401072810.1016/j.bbrc.2004.04.139

18 

E P Bonilla C C Akoh S Sellappan G Krewer Phenolic content and antioxidant capacity of muscadine grapesJ Agricultural Food Chem20035118549750310.1021/jf030113c

19 

F Mattivi R Guzzon U Vrhovsek M Stefanini R Velasco Metabolite Profiling of Grape: Flavonols and AnthocyaninsJ Agricultural Food Chem20065420769270210.1021/jf061538c

20 

K W Singletary M J Stansbury M Giusti R B Van Breemen M Wallig A Rimando Inhibition of Rat Mammary Tumorigenesis by Concord Grape Juice ConstituentsJ Agricultural Food Chem200351257280610.1021/jf030278l

21 

O Zendulka L Zahradníková J Totušek The Influence of Trans-resveratrol and Quercetin on the Activity of CYP1A2 in RatJ Food Sci20082660410.17221/244/2008-CJFS

22 

R Mikstacka J Gnojkowski W B Dubowska Effect of natural phenols on the catalytic activity of cytochrome P450 2E1Acta Biochim Polonica200249491725

23 

M L Veronese L P Gillen J P Burke E P Dorval W W Hauck E Pequignot Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceJ Clin Pharmacol2003438831910.1177/0091270003256059

24 

A Romani P Pinelli C Galardi G Sani A Cimatob D Heimler Polyphenols in greenhouse and open-air-grown lettuceFood Chem20027933374210.1016/S0308-8146(02)00170-X

25 

R Llorach A M Sánchez T Barberán F Ferreres Characterisation of polyphenols and antioxidant properties of five lettuce varieties and escaroleFood Chem20081083102838

26 

A Fadzilah A G Madihah Z T Siti K H Khadijah Stability of Bromelain-Polyphenol Complex in Pineapple JuiceJ Teknologi2008492738

27 

M Hidaka M Nagata Y Kawano H Sekiya H Kai K Yamasaki Inhibitory Effects of Fruit Juices on Cytochrome P450 2C9 Activity in vitroBiotechnol Biochem20087224061110.1271/bbb.70511

28 

J Lachman D Proněk A Hejtmánková J Dudjak V Pivec K Faitová Total polyphenol and main flavonoid antioxidants in different onion (Allium cepa L.) varietiesHorticultural Sci2003304142710.17221/3876-HORTSCI

29 

C Teyssier M J Amiot N Mondy J Auger R Kahane M H Siess Effect of onion consumption by rats on hepatic drug-metabolizing enzymesFood Chem Toxicol20013910981710.1016/s0278-6915(01)00056-4

30 

S N Green Health Benefits of Beets,ddsgreen@bellsouth.netThis e-mail address is being protected from spam bots2010http://www.sngreen.com/

31 

Y Wang C Yang C Liu M Xu S Li L Yang Effects of Bagging on Volatiles and Polyphenols in “Wanmi” Peaches during Endocarp Hardening and Final Fruit Rapid Growth StagesJ Food Sci20107594556010.1111/j.1750-3841.2010.01817.x

32 

B S Siddiqui T Gulzar S Begum A F Piptigrine A new insecticidal amide from Piper nigrum LinnNatural Product Res2004185473710.1080/14786410310001608028

33 

S K Yamsani R Gannu A Devandla V V Yamsani C R Palem S K Ravula Effect of ketoconazole and java plum pretreatment on intestinal transport of buspirone across rat intestineActa Pharm Sci20105244618

34 

H J Kim M H Yu I S Lee Inhibitory effects of methanol extract of plum (Prunus salicina L., cv. ‘Soldam’) fruits against benzo (α) pyrene-induced toxicity in miceFood Chem Toxicol2008461134071310.1016/j.fct.2008.08.012

35 

A P Kulkarni H S Mahal S Kapoor S M Aradhya In vitro studies on the binding, antioxidant, and cytotoxic actions of punicalaginJ Agricultural Food Chem2007554149150010.1021/jf0626720

36 

G W Plumb D P Teresa S S Buelga C R Gonzalo J C Williamson G Antioxidant properties of gallocatechin and prodelphinidins from pomegranate peelRedox Rep2002741416

37 

A V Sorokin B Duncan R Panetta P D Thompson Rhabdomyolysis Associated With Pomegranate Juice ConsumptionAmJ Cardiol2006985705610.1016/j.amjcard.2006.03.057

38 

B Cerdá F A T Barberán J C Espín Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variabilityJ Agricultural Food Chem20055322273510.1021/jf049144d

39 

F M Sacks A Lichtenstein L V Horn W Harris P K Etherton M Winston Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition CommitteeCirculation2006113710347810.1161/CIRCULATIONAHA.106.171052

40 

V Ivana M Kalam Cancer Inhibition by Inositol Hexaphosphate (IP6) and Inositol: From Laboratory toClin Nutr J20031331137788410.1093/jn/133.11.3778S

41 

P M Mrozikiewicz A Bogacz B Czerny M Karasiewicz R Kujawski P L Mikolajczak The influence of a standardized soybean extract (Glycine max) on the expression level of cytochrome P450 genes in vivoGinekologia Polska201081751636

42 

Super foods2011http://www.superfoodsrx.com/superfoods/spinach/spinach-in-the-eyes.html

43 

A Umek S Kreft T Kartnig B Heydel Quantitative phytochemical analyses of six hypericum species growing in sloveniaPlanta Med19996543889010.1055/s-2006-960798

44 

E C Tatsis S Boeren V Exarchou A N Troganis J Vervoort Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MSPhytochemistry20076833839310.1016/j.phytochem.2006.11.026

45 

B J Gurley A Swain D K Williams G Barone S K Battu Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokineticsMol Nutr Food Res20085277728110.1002/mnfr.200700081

46 

Substance in tangerines fights obesity and protects against heart disease2011http://schulich.uwo.ca/news/index1.php?article=001444

47 

J T Backman J Mäenpää D J Belle S A Wrighton K T Kivistö P J Neuvonen Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylationClin Pharmacol Ther20006743829010.1067/mcp.2000.105756

48 

List of Raw Foods High in Lutein2006http://www.treatment-skincare.com/September-2006/Lutein-Zeaxanthin/Raw-Foods.html

49 

The Power of Super Food2011http://www.superfoodsrx.com/superfoods/tomatoes/the-power-of-red.html

50 

P Palozza R E Simone A Catalano M C Mele Tomato Lycopene and Lung Cancer Prevention: From Experimental to Human StudiesCancers20113223335710.3390/cancers3022333

51 

super Food2011http://www.superfoodsrx.com/superfoods/oranges/the-power-of-flavonoids.html

52 

A Bhagat S Bavaskar J A Tamboli A B Nighute S B Bhise Effect of orange juice on the bioavailability of carbamazepineJ Pharm Res2009211203

53 

J D Reber D L Eggett T L Parker Antioxidant capacity interactions and a chemical/structural model of phenolic compounds found in strawberriesInt J Food Sci Nutr20116254455210.3109/09637486.2010.549115

54 

P M Kidd Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extractsAltern Med Rev200914322672

55 

Plant Culture Reagents2011http://www.sigmaaldrich.com/life-science/nutrition-research/learning-center/plant-profiler/silybum-marianum.html

56 

U T Subehan S Kadota Y Tezuka Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrumPlanta Med200672652732

57 

S Tsukamoto K Tomise K Miyakawa B C Cha T Abe T Hamada CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepperBioorganic Med Chem20021092981510.1016/s0968-0896(02)00130-x

58 

S B Lotito B Frei Relevance of apple polyphenols as antioxidants in human plasma: contrasting in vitro and in vivo effectsFree Radical Biol Med20043622011210.1016/j.freeradbiomed.2003.10.005

59 

C Pohl F Will H Dietrich D Schrenk Cytochrome P450 1A1 Expression and Activity in Caco-2 Cells: Modulation by Apple Juice Extract and Certain Apple PolyphenolsJ Agricultural Food Chem2006542610262810.1021/jf061791c

60 

L Wada B Ou Antioxidant activity and phenolic content of Oregon caneberriesJ Agricultural Food Chem20025012349550010.1021/jf011405l

61 

T J Hager L R Howard R Liyanage J O Lay R L Prior Ellagitannin composition of blackberry as determined by HPLC-ESI-MS and MALDI-TOF-MSJ Agricultural Food Chem20085636617010.1021/jf071990b

62 

M Paolinia J Barillaria M Broccolia L Pozzettia P Peroccob G C Fortia Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymesCancer Lett19991451-2354210.1016/s0304-3835(99)00225-6

63 

M Giorgi M Cheroni H I Saccomanni D Carlo S Yun G Effect of oral co-administration of frozen-dried grapefruit juice on pharmacokinetics of tramadol in dogsIranian J Vet Res201112134

64 

H Takanaga A Ohnishi H Murakami H Matsuo S Higuchi A Urae Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjectsClin Pharmacol Ther20006732011510.1067/mcp.2000.104215

65 

R Sultana A Ullah M M Akbor M Azad A Latif A Hasnat Effect of Orange Juice on Bioavailability of LevofloxacinJ Appl Res2008813442

66 

A V Kamath M Yao Y Zhang S Chong Effect of fruit juices on the oral bioavailability of fexofenadine in ratsJ Pharm Sci200594223342

67 

S R Penzak E P Acosta M Turner D J Edwards Y Y Hon H D Desai Effect of Seville orange juice and grapefruit juice on indinavir pharmacokineticsJ Clin Pharmacol2002421011657010.1177/009127002401382650

68 

Y Akira K Yuji F Tomoe H Tomoko Y Shinichi M Mika The effects of orange juice and lemon juice on the pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjectsKitasato Med J2007371227

69 

H Sorkhi A A Moghadamnia P Amir M Firoozjahi A R Oaliaee F Aghamolki Effects of Orange, Tangerine, and Grapefruit Juices on Pharmacokinetic Parameters of Cyclosporine A in RatsIranian J Med Sci2007321457

70 

J J Lilja K Raaska P J Neuvonen Effects of orange juice on the pharmacokinetics of atenololEur J Clin Pharmacol2005615-63374010.1007/s00228-005-0930-9

71 

J J Lilja L J Patinen P J Neuvonen Orange juice substantially reduces the bioavailability of the -adrenergic-blocking agent celiprololClin Pharmacol Ther20047518490

72 

B Auclair D E Nix R D Adam G T James C A Peloquin Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or AntacidsAntimicrob Agents Chemother2001453810410.1128/AAC.45.3.810-814.2001

73 

M Nagata M Hidaka H Sekiya Y Kawano K Yamasaki M Okumura Effects of Pomegranate Juice on Human Cytochrome P450 2C9 and Tolbutamide Pharmacokinetics in Rats. Drug Metabolism and DispositionDrug Metab Dispos2007352302510.1124/dmd.106.011718

74 

Z Wang M A Hamman S M Huang L J Lesko S D Hall Effect of St John's wort on the pharmacokinetics of fexofenadineClin Pharmacol Ther200271641442010.1067/mcp.2002.124080

75 

X Jiang K M Williams W S Liauw A J Ammit B D Roufogalis C C Duke Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsBr J Clin Pharmacol200457559260110.1111/j.1365-2125.2003.02051.x

76 

P Smith The Influence of St. John’s Wort on the Pharmacokinetics and Protein Binding of Imatinib MesylatePharmacotherapy2004241115081410.1592/phco.24.16.1508.50958

77 

J T Backman J Mäenpää D J Belle S A Wrighton K T Kivistö P J Neuvonen Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylationClin Pharmacol Ther200067438290

78 

E H Jang J Y Choi C S Park S K Lee C E Kim H J Park Effects of green tea extract administration on the pharmacokinetics of Clozapine in ratsJ Pharm Pharmacol20055733116

79 

I Junkoa K Tsutomua I Hiromitsua T Kimikob Y Tsuneakia O Tetsujia The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humansPharmacogenet Genom2011212849310.1097/fpc.0b013e32834300cc

80 

Y Uesawa K Mohri Effects of cranberry juice on Nifedipine pharmacokinetics in ratsJ Pharm Pharmacol200658810677210.1211/jpp.58.8.0007

81 

U I Schwarz D Seemann R Oertel S Miehlke E Kuhlisch M F Fromm Grapefruit juice ingestion significantly reduces talinolol bioavailabilityClin Pharmacol Therapeutics200577291301

82 

O P Yin N Gallagher A Li W Zhou R Harrell H Schran Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy ParticipantsJ Clin Pharmacol201050218894

83 

C P Siegers R Pentz M Younes Effect of (+)-catechin on the pharmacokinetics of carbamazepine in rabbitsArzneimittelforschung1982321114402

84 

L H Wang K Y Hsu Y S Uang F L Hsu L M Yang S J Lin Caffeic acid improves the bioavailability of L-dopa in rabbit plasmaPhytother Res20102468526010.1002/ptr.3031

85 

Y J Piao J S Choi Enhanced bioavailability of verapamil after oral administration with hesperidin in ratsArch Pharm Res20083145184010.1007/s12272-001-1187-4

86 

H Juan B Terhaag Z Cong Z B Kui Z R Hua W Feng Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteersEur J Clin Pharmacol2007637663810.1007/s00228-007-0298-0

87 

W Zhang T Tan L Y Lim Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats. Drug Metabolism and DispositionDrug Metab Dispos2007351110510.1124/dmd.106.011072

88 

C K Lee S H Ki J S Choi Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcuminBiopharm Drug Dispos20113242455110.1002/bdd.754

89 

W X Peng H D Li H H Zhou Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteersEur J Clin Pharmacol200359323778

90 

K Rajnarayana M S Reddy D R Krishna Diosmin pretreatment affects bioavailability of metronidazoleEur J Clin Pharmacol20035812803710.1007/s00228-002-0543-5

91 

J H Chunga D H Choi J S Choi Effects of Oral Epigallocatechin Gallate on the Oral Pharmacokinetics of Verapamil in RatsBiopharm Drug Dispos200930290310.1002/bdd.644

92 

S C Shin J S Choi Effects of Epigallocatechin Gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in ratsAnticancer Drugs20092075849210.1097/CAD.0b013e32832d6834

93 

X Li J S Choi Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in ratsInt J Pharm20073371-21889310.1016/j.ijpharm.2007.01.002

94 

D Singh Effect of Soybean Administration on Pharmacokinetics of Carbamazepine and Omeprazole. Dissertation submitted to Rajiv Gandhi University of Health Sciences2006626

95 

S C Shin C Li J S Choi Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicaleinPharmazie200964957983

96 

M Y Lai S L Hsiu Y C Hou S Y Tsai P D Chao Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of ScutellariabaicalensisPlanta Med20047021329 10.1055/s-2004-815489

97 

Y A Cho D H Choi J S Choi Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in ratsJ Pharm Pharmacol20096168253410.1211/jpp.61.06.0017

98 

Y Chen X Jia J Chen J Wang M Hu The Pharmacokinetics of Raloxifene and Its Interaction with Apigenin in RatMolecules2010151184788710.3390/molecules15118478

99 

E B Mougey J E Lang X Wen J J Lima Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of MontelukastJ Clin Pharmacol20115157516010.1177/0091270010374472

100 

J S Choi S C Shin Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to ratsInt J Pharm20052921-21495610.1016/j.ejpb.2003.11.002

101 

X Li J K Yun J S Choi Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos2007283151710.1002/bdd.539

102 

B C Choi J S Choi H K Han Altered pharmacokinetics of paclitaxel by the concomitant use of morin in ratsInt J Pharm20063231-281510.1016/j.ijpharm.2006.05.046

103 

X Li J S Choi AAPS Annual Meeting and Exposition.2005https://www.neventum.com/tradeshows/aaps-annual-meeting-exposition#:~:text=AAPS%20Annual%20Meeting%20%26%20Exposition%20is%20taking%20place%20from%2016%20October,in%20the%20month%20of%20October.

104 

S J Choi S C Shin J S Choi Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetinArch Pharm Res20113423092410.1007/s12272-011-0217-x

105 

D H Choi C Li J S Choi Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetinJ Pharm Pharmacol20106279082210.1211/jpp.62.07.0012

106 

C Li S C Lim J Kim J S Choi Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in ratsEur J Drug Metab Pharm20113631758210.1007/s13318-011-0036-y

107 

Y J Piao J S Choi Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in ratsJ Pharm Pharmacol2008605625910.1211/jpp.60.5.0008

108 

J S Choi K W Kang Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringinArch Pharm Res200831121631610.1007/s12272-001-2161-7

109 

H J Choi J S Choi Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in ratsArch Pharm Res20052889706

110 

X Wang Q Wang M E Morris Pharmacokinetic Interaction between the Flavonoid Luteolin and γ-Hydroxybutyrate in Rats: Potential Involvement of Monocarboxylate TransportersJ Am Pharm Assoc20081014755

111 

M Xu M Yang Y F Zheng Effect of Kaempferol on the Pharmacokinetics of Nifedipine in RatsJ Zhejiang Univ Med Sci2006351238

112 

C Li X Li J S Choi Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in ratsArch Pharm Res2009321133810.1007/s12272-009-1127-z

113 

Y Piao S C Shin J S Choi Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to ratsBiopharm Drug Dispos2008294245910.1002/bdd.593

114 

C P Yu P P Wu Y C Hou S P Lin S Y Tsai C T Chen Quercetin and Rutin Reduced the Bioavailability of Cyclosporine from Neoral, an Immunosuppressant, through Activating P-Glycoprotein and CYP 3A4J Agric Food201159946448

115 

K K Ah P P Whan P J Young Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteersEur J Clin Pharmacol20096566091410.1007/s00228-009-0627-6

116 

S C Shin J S Choi X Li Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in ratsInt J Pharm20063131-21449

117 

S P Hong D H Choi J S Choi Effects of Resveratrol on the Pharmacokinetics of Diltiazem and Its Major Metabolite, Desacetyldiltiazem, in RatsCardiovasc Ther20082642697510.1111/j.1755-5922.2008.00060.x

118 

J S Choi B C Choi K W Kang Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrolPharmazie20096414952

119 

E Chan A Hegde X Chen Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in ratsJ Pharm Pharmacol2009614451810.1211/jpp/61.04.0006

120 

C K Lee J S Choi Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in ratsPharmacology2010856350610.1159/000312690

121 

Wujw T H Tsai Effect of Silibinin on the Pharmacokinetics of Pyrazinamide and Pyrazinoic Acid in Rats. Drug Metab Dispos200735916031010.1124/dmd.107.014894

122 

C Li M Y Lee J S Choi Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in ratsPharmazie20106575104

123 

C S Kim S J Choi C Y Park C Li J S Choi Effects of Silybinin on the Pharmacokinetics of Tamoxifen and Its Active Metabolite, 4-Hydroxytamoxifen in RatsAnticancer20103017986

124 

U Fuhr S B Knopp A Jetter H Lück U Mengs The Effect of Silymarin on Oral Nifedipine PharmacokineticsPlanta Med2007731414293510.1055/s-2007-990256

125 

Y Han D Guo H H Zhou Z R Tan Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteersXenobiotica2009399694910.1080/00498250903060077

126 

S Pattanaik D Hota S Prabhakar P Kharbanda P Pandhi Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patientsPhytother Res20092391281610.1002/ptr.2676

127 

M J Jin H K Han Effect of Piperine, a Major Component of Black Pepper, on the Intestinal Absorption of Fexofenadine and Its Implication on Food-Drug InteractionJ Food Sci2010753936

128 

S Pattanaik D Hota S Prabhakar P Kharbanda P Pandhi Effect of piperine on the steady- state pharmacokinetics of phenytoin in patients with epilepsyPhytother Res20062086836

129 

G Bano R K Raina U Zutshi K L Bedi R K Johri S C Sharma Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteersEur J Clin Pharmacol1991416615710.1007/BF00314996

130 

K B Pandey S I Rizvi Current Understanding of Dietary Polyphenols and their Role in Health and Disease. Curr Nutr Food Sci2009542496310.2174/157340109790218058

131 

X Han T Shen H Lou Dietary Polyphenols and their Biological SignificanceInt J Mol Sci20078995088

132 

C A R Evans N J Miller G Paganga Antioxidant properties of phenolic compoundsTrends Plant Sci199724152910.1016/S1360-1385(97)01018-2

133 

K J Netter Mechanisms of monooxygenase induction and inhibitionPharmacol Ther19873311910.1016/0163-7258(87)90020-9

134 

L B Moore J M Maglich D D Mckee B Wisely T M Willson S A Kliewer Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) difine three pharmacologically distinct classes of nuclear receptorsMol Endocrinol200216597786

135 

H Waterbeemd H Lennernas P Artursson Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability2003246319

136 

G K Dresser D G Bailey The effects of fruit juices on drug disposition: a new model for drug interactionsEur J Clin Invest20033310610.1046/j.1365-2362.33.s2.2.x

137 

H Kim Y J Yoon J H Shon I J Cha J G Shin K H Liu Inhibitory Effects of Fruit Juices on CYP3A Activity. Drug Metabolism and Disposition2006344521523

138 

D Farkas D J Greenblatt Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studiesDrug Metab Toxicol20084438193

Keywords

Categories:

Subject: Review Article

Keywords:

Keywords

Polyphenols

CYP 450 isoenzymes

Pharmacokinetics

jats-html.xsl

×

Table details

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Review Article


Article page

13-23


Authors Details

Bhamre Vaibhav G., Deore Pranjal D., Amrutkar Rakesh D, Patil Vinod R.


Article History

Received : 05-12-2021

Accepted : 20-01-2022


Article Metrics


View Article As

 


Downlaod Files

   









Sitemap | Editorial and Ethical Policies | Open Access | Advertise | Feedback | Disclaimer
©2021 Current Trends In Pharmacy And Pharmaceutical Chemistry | Published by IP Innovative Publication Pvt. Ltd. (www.ipinnovative.com)
Online since 31st July, 2021
CTPPC is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.